101 related articles for article (PubMed ID: 18028276)
1. Ethanol dependence of alpha 1-antitrypsin C-terminal Lys truncation mediated by basic carboxypeptidases.
Matthiessen HP; Willemse J; Weber A; Turecek PL; Deiteren K; Hendriks D; Ehrlich HJ; Schwarz HP
Transfusion; 2008 Feb; 48(2):314-20. PubMed ID: 18028276
[TBL] [Abstract][Full Text] [Related]
2. Biochemical, molecular characterization, and glycoproteomic analyses of alpha(1)-proteinase inhibitor products used for replacement therapy.
Kolarich D; Turecek PL; Weber A; Mitterer A; Graninger M; Matthiessen P; Nicolaes GA; Altmann F; Schwarz HP
Transfusion; 2006 Nov; 46(11):1959-77. PubMed ID: 17076852
[TBL] [Abstract][Full Text] [Related]
3. Convenient high-resolution isoelectric focusing (IEF) method for the separation of alpha1-proteinase inhibitor (A1PI) isoforms in A1PI concentrates.
Weber A; Engelmaier A; Owen MC; Schwarz HP; Turecek PL
J Pharm Biomed Anal; 2007 Sep; 45(1):107-111. PubMed ID: 17629652
[TBL] [Abstract][Full Text] [Related]
4. Structural characterization of recombinant alpha-1-antitrypsin expressed in a human cell line.
Wang Z; Hilder TL; van der Drift K; Sloan J; Wee K
Anal Biochem; 2013 Jun; 437(1):20-8. PubMed ID: 23462539
[TBL] [Abstract][Full Text] [Related]
5. Preparation and properties of an alpha-1-protease inhibitor concentrate with high specific activity.
Mattes E; Matthiessen HP; Turecek PL; Schwarz HP
Vox Sang; 2001 Jul; 81(1):29-36. PubMed ID: 11520413
[TBL] [Abstract][Full Text] [Related]
6. Elucidating the effects of arginine and lysine on a monoclonal antibody C-terminal lysine variation in CHO cell cultures.
Zhang X; Tang H; Sun YT; Liu X; Tan WS; Fan L
Appl Microbiol Biotechnol; 2015 Aug; 99(16):6643-52. PubMed ID: 25947244
[TBL] [Abstract][Full Text] [Related]
7. Non enzymatic glycosylation of alpha-1-proteinase inhibitor of human plasma.
Phadke M; Billimoria FR; Ninjoor V
J Postgrad Med; 1998; 44(2):29-34. PubMed ID: 10703566
[TBL] [Abstract][Full Text] [Related]
8. Construction and expression of alpha 1-proteinase inhibitor mutants and the effects of these mutations on secretion of the variant inhibitors.
McCracken AA; Kruse KB; Valentine J; Roberts C; Yohannes TZ; Brown JL
J Biol Chem; 1991 Apr; 266(12):7578-82. PubMed ID: 2019587
[TBL] [Abstract][Full Text] [Related]
9. Production and characterization of a novel human recombinant alpha-1-antitrypsin in PER.C6 cells.
Ross D; Brown T; Harper R; Pamarthi M; Nixon J; Bromirski J; Li CM; Ghali R; Xie H; Medvedeff G; Li H; Scuderi P; Arora V; Hunt J; Barnett T
J Biotechnol; 2012 Dec; 162(2-3):262-73. PubMed ID: 23036927
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis for defective secretion of the Z variant of human alpha-1-proteinase inhibitor: secretion of variants having altered potential for salt bridge formation between amino acids 290 and 342.
McCracken AA; Kruse KB; Brown JL
Mol Cell Biol; 1989 Apr; 9(4):1406-14. PubMed ID: 2786139
[TBL] [Abstract][Full Text] [Related]
11. Biochemical efficacy and safety of a new, ready-to-use, liquid alpha-1-proteinase inhibitor, GLASSIA (alpha1-proteinase inhibitor (human), intravenous).
Sandhaus RA; Stocks J; Rouhani FN; Brantly M; Strauss P
COPD; 2014 Feb; 11(1):17-25. PubMed ID: 23822603
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary deposition and clearance of aerosolized alpha-1-proteinase inhibitor administered to dogs and to sheep.
Smith RM; Traber LD; Traber DL; Spragg RG
J Clin Invest; 1989 Oct; 84(4):1145-54. PubMed ID: 2794051
[TBL] [Abstract][Full Text] [Related]
13. Comparative biochemical efficacy analysis of an alpha
Li Z; Franke RM; Morris D; Yel L
Pulm Pharmacol Ther; 2022 Jun; 73-74():102124. PubMed ID: 35314325
[TBL] [Abstract][Full Text] [Related]
14. Isoelectric focusing phenotyping and denaturing gradient gel electrophoresis genotyping: a comparison of two methods in detection of alpha-1-antitrypsin variants.
Ljujic M; Topic A; Divac A; Nikolic A; Petrovic-Stanojevic N; Surlan M; Mitic-Milikic M; Radojkovic D
Transl Res; 2008 May; 151(5):255-9. PubMed ID: 18433707
[TBL] [Abstract][Full Text] [Related]
15. Cellular carboxypeptidases.
Skidgel RA; Erdös EG
Immunol Rev; 1998 Feb; 161():129-41. PubMed ID: 9553770
[TBL] [Abstract][Full Text] [Related]
16. Pathogen safety and characterisation of a highly purified human alpha
Kee S; Weber D; Popp B; Nowak T; Schäfer W; Gröner A; Roth NJ
Biologicals; 2017 May; 47():25-32. PubMed ID: 28377078
[TBL] [Abstract][Full Text] [Related]
17. alpha 1-Antitrypsin Christchurch, 363 Glu----Lys: mutation at the P'5 position does not affect inhibitory activity.
Brennan SO; Carrell RW
Biochim Biophys Acta; 1986 Sep; 873(1):13-9. PubMed ID: 3527273
[TBL] [Abstract][Full Text] [Related]
18. Carboxypeptidase M expressed by human bone marrow cells cleaves the C-terminal lysine of stromal cell-derived factor-1alpha: another player in hematopoietic stem/progenitor cell mobilization?
Marquez-Curtis L; Jalili A; Deiteren K; Shirvaikar N; Lambeir AM; Janowska-Wieczorek A
Stem Cells; 2008 May; 26(5):1211-20. PubMed ID: 18292211
[TBL] [Abstract][Full Text] [Related]
19. Functional and antigenic concentrations of alpha-1-proteinase inhibitor after administration for the prevention of chronic lung disease of prematurity.
Stiskal JA; Ito S; Cox DW; Shennan AT; O'Brien KK; Kelly EN; Longley TB; Rabinovitch M; Dunn MS
Biol Neonate; 1999 Sep; 76(3):134-43. PubMed ID: 10460951
[TBL] [Abstract][Full Text] [Related]
20. Purification of alpha-1-proteinase inhibitor. Preparation and properties of a therapeutic concentrate.
Coan MH
Am J Med; 1988 Jun; 84(6A):32-6. PubMed ID: 3260071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
